HOME > TOP STORIES

TOP STORIES

ORGANIZATION PhRMA Makes Yet Another Case for Perpetuation of New Drug Premium

October 31, 2013
REGULATORY Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo

October 30, 2013
REGULATORY 1st Committee Backs Japan Tobacco’s Hyperphosphatemia Treatment

October 30, 2013
ACADEMIA Beta Blockers “Inferior to Other Drugs,” Will Not Be Recommended as 1st–Line Treatments in New Hypertension GL

October 29, 2013
ORGANIZATION Generic Makers to Jointly Outsource GMP Inspections on Drug Substance Suppliers; Pilot to Begin by March

October 28, 2013
BUSINESS Teva’s Global Medical Director Says Biosimilars Can Cut Medical Costs

October 25, 2013
REGULATORY Regulatory Reform Council to Convene Public Discussion on Expansion of “Mixed Healthcare” on November 28

October 25, 2013
REGULATORY Diovan Panel Should Question 4 Key Figures to Dig into Scandal Further: Expert Member

October 24, 2013
REGULATORY MOF Demands Hefty Price Cuts for Long-Listed Products, Skeptical about Premium

October 23, 2013
BUSINESS Swiss Novartis Sees 22% Plunge in January-September Diovan Sales

October 23, 2013
ORGANIZATION No Clear Violation of Fair Competition Code in Diovan Case: Maker FTC Exec

October 22, 2013
BUSINESS Wholesalers’ Sluggish Price Settlement Rate Could Mar Reliability of Market Price Survey

October 22, 2013
ORGANIZATION JPMA Will Announce Response to Violation of PAL by Mitsubishi Tanabe in Near Future: Director General Goto

October 21, 2013
REGULATORY Ex-Health Minister Nagatsuma Eyes Unsworn Diet Testimony by Ex-Novartis Employee on Diovan Scandal

October 18, 2013
REGULATORY CSIMC Pricing Subcommittee OKs Indicator to Gauge Reasonableness of Premium’s Perpetuation

October 17, 2013
BUSINESS Gilead to Fully Enter Japan, File for Approval for Hepatitis C Treatment Sofosbuvir in 2014: President

October 16, 2013
BUSINESS Once-Weekly DPP-4 Inhibitors of MSD, Takeda to Bring New Dimension to Packed Market

October 15, 2013
BUSINESS Gilead to Enter Japan Full Force with Hepatitis C Treatment

October 11, 2013
REGULATORY CSIMC Pricing Subcommittee to Explore “Responses” to Diovan Uproar

October 10, 2013
ORGANIZATION Japan Self-Medication Industry Requests Health Minister to Remove JMA, JPA Members from OTC Drug Review Council

October 9, 2013

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…